HealthRX.com · Printable side-effect diary
Wegovy constipation diary by week and dose step
One line per week from your first injection: dose, number of bowel movements, stool type, straining and what you used to help. Bring it when a dose goes up or symptoms change, so the timing of your constipation can be compared with your dose steps.
Before week 1
Usual bowel pattern before Wegovytimes per week
Date of first injection
Planned or actual dates of each dose increase
Other medicines that can constipateopioids, iron, calcium, some antacids
Fiber, fluids or laxatives already in use
Weekly record
Stool type: 1 = hard lumps, 4 = smooth and soft, 7 = watery.
| Week | Dose (mg) | Bowel movements | Hardest stool type (1 to 7) | Straining or pain? | What helped | Notes |
|---|---|---|---|---|---|---|
Timing facts from the trials and label
- In pooled STEP 1 to 3, constipation was reported by 24.2% on semaglutide 2.4 mg and 11.1% on placebo over 68 weeks.[1]
- The share with constipation plateaued at about week 10, and a constipation episode lasted a median of 47 days on semaglutide vs 35 on placebo.[1]
- In STEP 4, constipation became less common over time in people who continued 2.4 mg.[1]
- The label says stomach side effects were most often reported during dose escalation.[2]
- After approval, ileus, intestinal obstruction and severe constipation including fecal impaction have been reported with semaglutide.[2]
Call instead of waiting for the next step
- Severe stomach pain that will not go away, with or without vomiting: stop Wegovy and call your healthcare provider right away.[2]
- Stomach problems that are severe or will not go away: tell your healthcare provider.[2]
- Upper stomach pain, fever, yellow skin or eyes, or clay-colored stools: call your healthcare provider.[2]
When you bring the diary
- Does my pattern look like it is settling, or getting worse with each dose step?
- Should the next increase wait until my bowels are more regular?
- Which laxative suits me, and for how long?
- Could another of my medicines be adding to the constipation?
Sources for the facts on this sheet
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022. PMID 34514682. https://pubmed.ncbi.nlm.nih.gov/34514682/
- Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection, for subcutaneous use, and Wegovy (semaglutide) tablets, for oral use: prescribing information and Medication Guide. Effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.